224,145 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 224,145 shares of Ocular Therapeutix in the second quarter, valued at approximately $2.2 million and representing a 0.10% stake. Institutional investors and hedge funds collectively own 59.21% of the company.
• Ocular Therapeutix reported a quarterly loss of $0.35 per share, beating estimates by $0.05, while revenue of $13.47 million slightly exceeded expectations. Analysts project a full-year loss of $1.47 per share.
• The stock opened at $10.82, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $25.75; insiders sold shares primarily to cover tax obligations related to equity awards.

Deutsche Bank AG acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 224,145 shares of the biopharmaceutical company's stock, valued at approximately $2,201,000. Deutsche Bank AG owned 0.10% of Ocular Therapeutix as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its position in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in Ocular Therapeutix during the 4th quarter worth $31,000. Hilton Head Capital Partners LLC acquired a new position in Ocular Therapeutix in the 4th quarter valued at $42,000. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix in the 4th quarter valued at $61,000. Finally, State of Wyoming bought a new stake in shares of Ocular Therapeutix during the 4th quarter valued at $78,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Up 0.5%

NASDAQ:OCUL opened at $10.82 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44. The firm's 50 day simple moving average is $9.66 and its 200 day simple moving average is $9.16. The company has a market cap of $2.38 billion, a PE ratio of -7.62 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The business had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.Ocular Therapeutix's revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the company earned ($0.39) EPS. On average, research analysts anticipate that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current year.

Insider Activity

In related news, insider Jeffrey S. Heier sold 3,296 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $10.78, for a total value of $35,530.88. Following the transaction, the insider directly owned 318,326 shares of the company's stock, valued at $3,431,554.28. The trade was a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 3,035 shares of the company's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $10.77, for a total value of $32,686.95. Following the completion of the sale, the insider owned 264,378 shares in the company, valued at $2,847,351.06. The trade was a 1.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 29,877 shares of company stock valued at $321,827. Company insiders own 3.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on OCUL shares. Needham & Company LLC restated a "buy" rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, May 5th. Royal Bank Of Canada reiterated an "outperform" rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Robert W. Baird increased their price objective on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an "outperform" rating in a research note on Thursday, June 18th. Wall Street Zen raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $25.75.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source